MovDisordV3, Main, Merge, bibRecord, 007484

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease

Identifieur interne : 007484 ( Main/Merge ); précédent : 007483; suivant : 007485

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease

Auteurs : R. A. Hauser [États-Unis] ; W. C. Koller [États-Unis] ; J. P. Hubble [États-Unis] ; T. Malapira [États-Unis] ; K. Busenbark [États-Unis] ; C. W. Olanow [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:00-0269467

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lévodopa, Antiparkinsonien, Carbidopa, Bromocriptine, Arrêt traitement, Chimiothérapie, Evolution, Homme, Ergot dérivé.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Bromocriptine, Carbidopa, Chemotherapy, Ergot derivatives, Evolution, Human, Levodopa, Parkinson disease, Treatment withdrawal.

Abstract

Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash-out of symptomatic medication. In this type of analysis it is critical to use a wash-out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day I to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash-out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 002C07
to stream PascalFrancis, to step Curation: 000114
to stream PascalFrancis, to step Checkpoint: 002A92

Links to Exploration step

Pascal:00-0269467

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease</title>
<author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>University of Miami</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hubble, J P" sort="Hubble, J P" uniqKey="Hubble J" first="J. P." last="Hubble">J. P. Hubble</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Ohio State University</s1>
<s2>Columbus, Ohio</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Malapira, T" sort="Malapira, T" uniqKey="Malapira T" first="T." last="Malapira">T. Malapira</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Busenbark, K" sort="Busenbark, K" uniqKey="Busenbark K" first="K." last="Busenbark">K. Busenbark</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>University of Kansas</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0269467</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0269467 INIST</idno>
<idno type="RBID">Pascal:00-0269467</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C07</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000114</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002A92</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Hauser R:time:course:of</idno>
<idno type="wicri:Area/Main/Merge">007484</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease</title>
<author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>University of Miami</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hubble, J P" sort="Hubble, J P" uniqKey="Hubble J" first="J. P." last="Hubble">J. P. Hubble</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Ohio State University</s1>
<s2>Columbus, Ohio</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Malapira, T" sort="Malapira, T" uniqKey="Malapira T" first="T." last="Malapira">T. Malapira</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Busenbark, K" sort="Busenbark, K" uniqKey="Busenbark K" first="K." last="Busenbark">K. Busenbark</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>University of Kansas</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Bromocriptine</term>
<term>Carbidopa</term>
<term>Chemotherapy</term>
<term>Ergot derivatives</term>
<term>Evolution</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Treatment withdrawal</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Carbidopa</term>
<term>Bromocriptine</term>
<term>Arrêt traitement</term>
<term>Chimiothérapie</term>
<term>Evolution</term>
<term>Homme</term>
<term>Ergot dérivé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash-out of symptomatic medication. In this type of analysis it is critical to use a wash-out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day I to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash-out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>Kansas</li>
<li>Ohio</li>
<li>État de New York</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name>
</region>
<name sortKey="Busenbark, K" sort="Busenbark, K" uniqKey="Busenbark K" first="K." last="Busenbark">K. Busenbark</name>
<name sortKey="Hubble, J P" sort="Hubble, J P" uniqKey="Hubble J" first="J. P." last="Hubble">J. P. Hubble</name>
<name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
<name sortKey="Malapira, T" sort="Malapira, T" uniqKey="Malapira T" first="T." last="Malapira">T. Malapira</name>
<name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007484 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007484 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:00-0269467
   |texte=   Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri